Formalin-fixed paraffin-embedded sample conditions for deep next generation sequencing.

INTRODUCTION Precision medicine is only possible in oncology practice if targetable genes in fragmented DNA, such as DNA from formalin-fixed paraffin-embedded (FFPE) samples, can be sequenced using next generation sequencing (NGS). The aim of this study was to examine the quality and quantity of DNA from FFPE cancerous tissue samples from surgically resected and biopsy specimens. METHODS DNA was extracted from unstained FFPE tissue sections prepared from surgically resected specimens of breast, colorectal and gastric cancer, and biopsy specimens of breast cancer. A total quantity of DNA ≥60 ng from a sample was considered adequate for NGS. The DNA quality was assessed by Q-ratios, with a Q-ratio >0.1 considered sufficient for NGS. RESULTS The Q-ratio for DNA from FFPE tissue processed with neutral-buffered formalin was significantly better than that processed with unbuffered formalin. All Q-ratios for DNA from breast, colorectal and gastric cancer samples indicated DNA levels sufficient for NGS. DNA extracted from gastric cancer FFPE samples prepared within the last 7 years is suitable for NGS analysis, whereas those older than 7 years may not be suitable. Our data suggested that adequate amounts of DNA can be extracted from FFPE samples, not only of surgically resected tissue but also of biopsy specimens. CONCLUSIONS The type of formalin used for fixation and the time since FFPE sample preparation affect DNA quality. Sufficient amounts of DNA can be extracted from FFPE samples of both surgically resected and biopsy tissue, thus expanding the potential diagnostic uses of NGS in a clinical setting.

[1]  Christoph Endrullat,et al.  Standardization and quality management in next-generation sequencing , 2016, Applied & translational genomics.

[2]  Somak Roy,et al.  Molecular Pathology Informatics. , 2016, Clinics in laboratory medicine.

[3]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.

[4]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[5]  Lila Kari,et al.  Additive methods for genomic signatures , 2016, BMC Bioinformatics.

[6]  S. Tommasi,et al.  The value of new high-throughput technologies for diagnosis and prognosis in solid tumors. , 2014, Cancer biomarkers : section A of Disease markers.

[7]  H. Varmus,et al.  Support for the Human Cancer Genome Project , 2005, Science.

[8]  Shujiro Okuda,et al.  Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer. , 2017, Human pathology.

[9]  Shujiro Okuda,et al.  Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine , 2016, Genome Medicine.

[10]  Christina M Lockwood,et al.  Design of targeted, capture-based, next generation sequencing tests for precision cancer therapy. , 2013, Cancer genetics.

[11]  C. Horak,et al.  Association of PIK3CA mutation with response (ExRx) to cetuximab (C) in metastatic (met) triple-negative breast cancer (TNBC). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Brenda Y. Hernandez,et al.  Robustness of Next Generation Sequencing on Older Formalin-Fixed Paraffin-Embedded Tissue , 2015, PloS one.

[13]  I. Salmon,et al.  Clinical Application of Targeted Next Generation Sequencing for Colorectal Cancers , 2016, International journal of molecular sciences.

[14]  Rakesh Nagarajan,et al.  Clinical next‐generation sequencing in patients with non–small cell lung cancer , 2015, Cancer.

[15]  A. Buzaid,et al.  Next-generation sequencing (NGS) in metastatic breast cancer (mBC) patients: Translation from sequence data into clinical practice. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. Desmedt,et al.  Impact of tumor sequencing on the use of anticancer drugs , 2014, Current opinion in oncology.

[17]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[18]  Andrew Fraser Worms in L.A. , 2003, Nature Genetics.

[19]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[20]  John D Pfeifer,et al.  Comparison of clinical targeted next-generation sequence data from formalin-fixed and fresh-frozen tissue specimens. , 2013, The Journal of molecular diagnostics : JMD.

[21]  Alexander Dobrovic,et al.  Sequence artifacts in DNA from formalin-fixed tissues: causes and strategies for minimization. , 2015, Clinical chemistry.

[22]  H. Varmus Genomic empowerment: the importance of public databases , 2002, Nature Genetics.

[23]  G. Nuovo,et al.  Comparison of formalin, buffered formalin, and Bouin's fixation on the detection of human papillomavirus deoxyribonucleic acid from genital lesions. , 1988, Laboratory investigation; a journal of technical methods and pathology.

[24]  G. Nuovo,et al.  The Effect of Aging of Formalin-fixed Paraffin-embedded Tissues on the In Situ Hybridization and Immunohistochemistry Signals in Cervical Lesions , 2013, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[25]  M. Marton,et al.  Pre-Analytical Considerations for Successful Next-Generation Sequencing (NGS): Challenges and Opportunities for Formalin-Fixed and Paraffin-Embedded Tumor Tissue (FFPE) Samples , 2016, International journal of molecular sciences.

[26]  C. Masselon,et al.  Beyond laser microdissection technology: follow the yellow brick road for cancer research. , 2014, American journal of cancer research.

[27]  H. Bear,et al.  Angiopoietin pathway gene expression associated with poor breast cancer survival , 2017, Breast Cancer Research and Treatment.

[28]  David E. Fisher,et al.  Precision medicine for cancer with next-generation functional diagnostics , 2015, Nature Reviews Cancer.

[29]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[30]  F. Collins,et al.  A new initiative on precision medicine. , 2015, The New England journal of medicine.

[31]  F. Collins,et al.  Aiming High--Changing the Trajectory for Cancer. , 2016, The New England journal of medicine.

[32]  C. Flowers,et al.  Costs and effectiveness of genomic testing in the management of colorectal cancer. , 2015, Oncology.

[33]  Nikesh S. Dattani,et al.  Mapping the Space of Genomic Signatures , 2014, PloS one.

[34]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.